Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Alex Digesu
Mirabegron &Ndash; A Selective &Szlig;3-Adrenoreceptor Agonist for the Treatment of Overactive Bladder
Research and Reports in Urology
Urology
Related publications
Mirabegron: A Beta-3 Agonist for Overactive Bladder
The Consultant Pharmacist
Discovery of Vibegron: A Potent and Selective 3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder
Persistence and Adherence With Mirabegron, a New Beta-3 Receptor Agonist, Versus Antimuscarinics in Overactive Bladder: Early Experience in Canada
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
AE9C90CB: A Novel, Bladder-Selective Muscarinic Receptor Antagonist for the Treatment of Overactive Bladder
British Journal of Pharmacology
Pharmacology
The Effect of Mirabegron, Used for Overactive Bladder Treatment, on Female Sexual Function: A Prospective Controlled Study
BMC Urology
Medicine
Reproductive Medicine
Urology
OnabotulinumtoxinA for the Treatment of Overactive Bladder
Research and Reports in Urology
Urology
Botulinum Toxin a for the Treatment of Overactive Bladder
Toxins
Mutagenesis
Toxicology
Health
New Developments in the Management of Overactive Bladder: Focus on Mirabegron and onabotulinumtoxinA
Therapeutics and Clinical Risk Management
Long-Term Safety and Efficacy of the Novel Β3 -Adrenoreceptor Agonist Vibegron in Japanese Patients With Overactive Bladder: A Phase III Prospective Study
International Journal of Urology
Urology
